Consolidated Financial Statements, Schedule of Expenditures of Federal Awards, Internal Control and Compliance (With Supplementary Information) and Independent Auditor's Reports

December 31, 2021 and 2020



<u>Index</u>

	<u>Page</u>
Independent Auditor's Report	2
Consolidated Financial Statements	
Consolidated Statements of Financial Position	5
Consolidated Statements of Activities and Changes in Net Assets	6
Consolidated Statements of Functional Expenses	8
Consolidated Statements of Cash Flows	10
Notes to Consolidated Financial Statements	12
Supplementary Information	
Schedule of Expenditures of Federal Awards	33
Notes to Schedule of Expenditures of Federal Awards	34
Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	35
Independent Auditor's Report on Compliance for Each Major Federal Program and Report on Internal Control over Compliance Required by the Uniform Guidance	37
Schedule of Findings and Questioned Costs	40



Independent Auditor's Report

To the Board of Directors Whitney M. Young, Jr. Health Center, Inc. and Foundation

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Whitney M. Young, Jr. Health Center, Inc. and Foundation (the "Organization"), which comprise the consolidated statements of financial position as of December 31, 2021 and 2020, and the related consolidated statements of activities and changes in net assets, functional expenses and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Organization as of December 31, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. The financial statements of Whitney M. Young, Jr. Foundation were not audited in accordance with *Government Auditing Standards*.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern within one year after the date that the consolidated financial statements are available to be issued.



Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The schedule of expenditures of federal awards, as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.



Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated May 11, 2022 on our consideration of the Organization's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Organization's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Organization's internal control over financial reporting and compliance.

CohnReynickIIP

New York, New York May 11, 2022

Consolidated Statements of Financial Position December 31, 2021 and 2020

<u>Assets</u>

	 2021	 2020
Current assets Cash Short-term investments Patient accounts receivable, net 340B pharmacy program receivable Grants and contracts and contributions receivable Prepaid expenses and other current assets	\$ 5,722,143 11,557,471 1,804,136 794,846 752,750 484,220	\$ 5,842,536 10,002,971 1,337,608 463,515 760,053 587,323
Total current assets	 21,115,566	 18,994,006
Long-term investments Deferred compensation Property and equipment, net Security deposits	 14,705,197 447,503 6,107,339 162,350	 12,293,208 404,382 6,244,397 162,350
	 21,422,389	 19,104,337
Total	\$ 42,537,955	\$ 38,098,343
Liabilities and Net Assets		
Current liabilities Accounts payable and accrued expenses Accrued payroll and employee benefits Due to third-party payors Current maturities of long-term debt Refundable advances	\$ 875,804 837,145 518,387 - 1,152,021	\$ 541,193 1,150,959 80,672 424,729 1,442,803
Total current liabilities	3,383,357	3,640,356
Noncurrent liabilities Deferred rent Asset retirement obligation Deferred compensation Long-term debt, less current maturities	 187,253 25,075 447,503 -	 223,205 25,075 404,382 1,613,971
Total liabilities	 4,043,188	 5,906,989
Commitments and contingencies		
Net assets Without donor restrictions With donor restrictions	 38,203,608 291,159	 31,938,767 252,587
Total net assets	 38,494,767	 32,191,354
Total	\$ 42,537,955	\$ 38,098,343

See Notes to Consolidated Financial Statements.

Consolidated Statement of Activities and Changes in Net Assets Year Ended December 31, 2021

	Without Donor Restrictions	With Donor Restrictions	Total
Revenue			
Patient services (net of contractual			
allowances and discounts)	\$ 9,335,303	\$ -	\$ 9,335,303
DHHS grants	7,646,184	-	7,646,184
Contract services and other grants	1,733,648	-	1,733,648
In-kind contributions	620,920	-	620,920
Contributions	25,143	42,100	67,243
340B pharmacy program	7,391,465	-	7,391,465
Investment return, net	1,177,915	-	1,177,915
Other	2,058,710	-	2,058,710
Net assets released from restrictions	3,528	(3,528)	-
Total revenue	29,992,816	38,572	30,031,388
Expenses			
Salaries and related benefits	12,648,282	-	12,648,282
Other than personnel services	10,302,957	-	10,302,957
Depreciation and amortization	776,736		776,736
Total expenses	23,727,975		23,727,975
Changes in net assets	6,264,841	38,572	6,303,413
Net assets			
Beginning	31,938,767	252,587	32,191,354
End	\$ 38,203,608	\$ 291,159	\$ 38,494,767

Consolidated Statement of Activities and Changes in Net Assets Year Ended December 31, 2020

	Without Donor Restrictions	With Donor Restrictions	Total
Revenue			
Patient services (net of contractual			
allowances and discounts)	\$ 10,060,618	\$ -	\$ 10,060,618
DHHS grants	6,632,710	-	6,632,710
Contract services and other grants	2,608,865	-	2,608,865
In-kind contributions	392,302	-	392,302
Contributions	170,635	239,020	409,655
340B pharmacy program	8,054,673	-	8,054,673
Investment return, net	1,150,838	-	1,150,838
Other	28,480	-	28,480
Net assets released from restrictions	287,122	(287,122)	
Total revenue	29,386,243	(48,102)	29,338,141
Expenses			
Salaries and related benefits	13,611,658	-	13,611,658
Other than personnel services	8,915,898	-	8,915,898
Depreciation and amortization	797,264		797,264
Total expenses	23,324,820		23,324,820
Changes in net assets	6,061,423	(48,102)	6,013,321
Net assets			
Beginning	25,877,344	300,689	26,178,033
End	\$ 31,938,767	\$ 252,587	\$ 32,191,354

See Notes to Consolidated Financial Statements.

Consolidated Statement of Functional Expenses Year Ended December 31, 2021

Program Services

						N N N										
					ĕ	Behavioral			Tot	Total Program	Ğ	General and				
	Me	Medical		Dental		Health	₽	Pharmacy		Services	Adi	Administrative	Fur	Fundraising		Total
Salaries and wages	\$ 2	5,751,229	ф	939,024	ŝ	1,270,445	θ		÷	7,960,698	ф	2,391,660	¢	58,535	φ	10,410,893
Fringe benefits and payroll taxes	Ĺ,	1,344,415		181,369		278,899				1,804,683		423,272		9,434		2,237,389
Consultants and contractual services		324,141		177,150		21,515				522,806		262,416				785,222
Medical, dental and pharmacy supplies		330,268		182,983		129,781		4,389,420		5,032,452		3,342				5,035,794
Donated vaccines		620,920						1		620,920				,		620,920
Professional fees		140,859		42,917		319,522				503,298		9,561				512,859
Translation services		79,549		5,612						85,161						85,161
Occupancy		221,521		113,387		201,063		37,597		573,568		170,281		11,518		755,367
Insurance		50,360		5,977		16,336		1		72,673		51,507		1		124,180
Repairs and maintenance and miscellaneous																
equipment		329,232		26,359		84,534				440,125		36,690				476,815
Telephone, cable and cell phones		133,920		16,882		28,675				179,477		17,458		996		197,901
Printing, publications, copier and postage		34,925		3,204		4,888		•		43,017		20,214		3,660		66,891
Office, housekeeping and food supplies		54,595		4,111		10,679		•		69,385		27,651		7,159		104,195
Information technology and data processing		368,306		13,155		81,916				463,377		584,531		4,615		1,052,523
Advertising and promotion		20,928				2,175				23,103		94,143		3,539		120,785
Office expenses		63,701		13,860		10,721		•		88,282		43,049		20		131,401
Travel, conferences, conventions and meetings		53,526		3,604		789		•		57,919		12,150		•		70,069
Dues and licenses		17,208		1,826		10,790				29,824		69,508				99,332
Other		3,291		375		963				4,629		57,913		1,000		63,542
Depreciation and amortization		367,216		139,631		139,697				646,544		130,192				776,736
Total functional expenses	\$ 10,	\$ 10,310,110	¢	1,871,426	¢	2,613,388	\$	4,427,017	¢	19,221,941	¢	4,405,538	ф	100,496	¢	23,727,975

Consolidated Statement of Functional Expenses Year Ended December 31, 2020

Program Services

						2										
					å	Behavioral			Tot	Total Program	Ŏ	General and				
		Medical		Dental		Health	₽	Pharmacy		Services	PA	Administrative	Func	Fundraising	F	Total
Salaries and wages	φ	6,388,343	θ	836,085	ф	1,574,812	ŝ	•	φ	8,799,240	ŝ	2,294,877	ŝ	68,389	\$ 1	11,162,506
Fringe benefits and payroll taxes		1,438,441		167,210		355,203		•		1,960,854		477,573		10,725	2	2,449,152
Consultants and contractual services		332,679		150,073		2,340				485,092		208,537				693,629
Medical, dental and pharmacy supplies		386,933		105,000		130,041		4,118,943		4,740,917		626			4	4,741,543
Donated vaccines		392,302								392,302						392,302
Professional fees		184,772				120,070				304,842		13,418				318,260
Translation services		103,692		2,927		•		•		106,619						106,619
Occupancy		103,473		101,580		154,974		33,038		393,065		149,504		11,465		554,034
Insurance		53,289		7,223		15,879				76,391		45,754		,		122,145
Repairs and maintenance and																
miscellaneous equipment		203,451		21,601		51,418		•		276,470		42,348				318,818
Telephone, cable and cell phones		128,344		14,284		31,095		•		173,723				938		174,661
Printing, publications, copier and postage		30,098		1,764		5,387				37,249		15,798		3,488		56,535
Office, housekeeping and food supplies		62,956		3,132		15,453		•		81,541		14,918		884		97,343
Information technology and data processing		177,813		8,257		78,822		•		264,892		356,307		3,547		624,746
Advertising and promotion		35,574				2,300				37,874		40,915		3,983		82,772
Office expenses		59,394		15,796		9,480				84,670		12,836		25		97,531
Travel, conferences, conventions and meetings	6	34,507		3,484		3,857		•		41,848		15,908		35		57,791
Dues and licenses		3,417		512		5,094		•		9,023		86,529		56		95,608
Bad debt		172,434		44,494		22,173		•		239,101						239,101
Other		5,592		5,779		15,500		•		26,871		115,589				142,460
Depreciation and amortization		359,214		151,713		142,104				653,031		144,233				797,264
Total functional expenses	ф	10,656,718	ф	1,640,914	ф	2,736,002	ф	4,151,981	ф	19,185,615	ф	4,035,670	ф	103,535	\$ 23	23,324,820

See Notes to Consolidated Financial Statements.

Consolidated Statements of Cash Flows Years Ended December 31, 2021 and 2020

	2021	2020
Cash flows from operating activities Cash received from patient services and pharmacy program Cash received from contracts and other grants Cash received for restricted donations Cash received from other Cash paid to employees Cash paid to vendors	<pre>\$ 16,366,624 9,121,496 42,100 20,010 (12,962,096) (9,280,275)</pre>	\$ 17,826,501 9,416,041 239,020 28,480 (13,776,987) (8,694,263)
Net cash provided by operating activities	3,307,859	5,038,792
Cash flows from investing activities Purchase of investments Purchase of property and equipment Net cash used in investing activities	(2,788,574) (639,678) (3,428,252)	(6,297,257) (358,333) (6,655,590)
Cash flows from financing activities Proceeds from long-term debt		2,038,700
Net cash provided by financing activities		2,038,700
Net (descrease) increase in cash	(120,393)	421,902
Cash, beginning	5,842,536	5,420,634
Cash, end	\$ 5,722,143	\$ 5,842,536

Consolidated Statements of Cash Flows Years Ended December 31, 2021 and 2020

	 2020	 2019
Reconciliation of changes in net assets to net cash provided by operating activities		
Changes in net assets	\$ 6,303,413	\$ 6,013,321
Adjustments to reconcile changes in net assets to net cash provided by operating activities		
Depreciation and amortization	776,736	797,264
Investment return, net	(1,177,915)	(1,150,838)
Gain on extinguishment of long-term debt	(2,038,700)	-
Deferred rent	(35,952)	(51,235)
Changes in operating assets and liabilities		
Patient accounts receivable	(466,528)	(387,119)
340B pharmacy program receivable	(331,331)	128,329
Grants and contracts and contributions receivable	7,303	(74,674)
Prepaid expenses and other current assets	103,103	(259,374)
Accounts payable and accrued expenses	334,611	139,942
Accrued payroll and employee benefits	(313,814)	(165,329)
Due to third-party payors	437,715	(30,000)
Refundable advances	 (290,782)	 78,505
Net cash provided by operating activities	\$ 3,307,859	\$ 5,038,792
Supplemental disclosure of noncash financing activity Gain on extinguishment of long-term debt	\$ 2,038,700	\$ _

See Notes to Consolidated Financial Statements.

Notes to Consolidated Financial Statements December 31, 2021 and 2020

Note 1 - Organization

Whitney M. Young, Jr. Health Center, Inc. (the "Center") is a Federally Qualified Health Center ("FQHC") that operates healthcare centers in Albany and Rensselaer counties, New York. The Center provides a broad range of health services to a largely medically underserved population.

Whitney M. Young, Jr. Foundation (the "Foundation") was created solely and exclusively to solicit contributions to support the Center. The Center is the sole member of the Foundation and is, therefore, considered the parent company.

The U.S. Department of Health and Human Services (the "DHHS") provides substantial support to the Center. The Center is obligated under the terms of the DHHS grants to comply with specified conditions and program requirements set forth by the grantor.

Note 2 - Significant accounting policies

Basis of presentation

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America ("GAAP").

The accompanying consolidated financial statements include the accounts of the Center and Foundation (collectively, the "Organization"). All intercompany transactions and account balances have been eliminated in consolidation.

Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Classification of net assets

The Organization reports information regarding its consolidated financial position and activities according to the following two categories:

<u>Net assets without donor restrictions</u>: are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Organization. These net assets may be used at the discretion of the Organization's management and the board of directors.

<u>Net assets with donor restrictions</u>: are subject to stipulations imposed by donors and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Organization or by the passage of time. Other donor restrictions are perpetual in nature, where by the donor has stipulated the funds be maintained in perpetuity.

Donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the statements of activities and changes in net assets. Net assets with donor restrictions amounted to \$291,159 and \$252,587 at December 31, 2021 and 2020, respectively.

Notes to Consolidated Financial Statements December 31, 2021 and 2020

Cash and cash equivalents

The Organization maintains its cash and cash equivalents in bank deposit accounts that, at times, may exceed federally insured limits. The Organization has not experienced any losses in such accounts. All highly-liquid investments with maturities of three months or less when purchased are considered to be cash equivalents.

Investments

Investments are comprised of mutual funds, common stocks, exchange traded funds, bonds, U.S. Treasury and agency securities and collective investment funds that are valued at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Purchases and sales of securities are recorded on a trade-date basis. Interest income, realized and unrealized gains and losses are recorded on the accrual basis. Dividends are recorded on the ex-dividend date.

Investment return, net is reported in the statements of activities and changes in net assets and consists of interest and dividend income and realized and unrealized gains and losses.

Patient services receivable

The collection of receivables from third-party payors and patients is the Center's primary source of cash for operations and is critical to its operating performance. The primary collection risks relate to uninsured patient accounts and patient accounts for which the primary insurance payor has paid, but patient responsibility amounts (deductibles and copayments) remain outstanding. Patient receivables from third-party payors are carried at a net amount determined by the original charge for the service provided, less an estimate made for contractual adjustments or discounts provided to third-party payors.

Receivables due directly from patients are carried at the original charge for the service provided less discounts provided under the Center's charity care policy, less amounts covered by third-party payors and less an estimated allowance for doubtful receivables. Management determines the allowance for doubtful accounts by identifying troubled accounts and by historical experience applied to an aging of accounts. The Center considers accounts past due when they are outstanding beyond 60 days with no payment. The Center generally does not charge interest on past due accounts. Patient receivables are written off against the allowance for doubtful accounts when deemed uncollectible. Recoveries of receivables previously written off are recorded as a reduction of bad debt expense when received.

Grants and contracts receivable

Grants and contracts receivable consist of costs under the grant and contract agreements that were incurred prior to year-end for which payment has not been received. Grants and contracts receivable credit risk is limited due to the nature of the grants and contracts. The Organization regularly monitors its grants and contracts receivable by investigating delayed payments and differences when payments received do not conform to the amount billed. The Organization considers all grants and contracts as collectible.

Property and equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from three to 40 years. Leasehold improvements are amortized over the shorter of the useful life of the asset or the lease term. Expenditures over \$5,000 are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation and amortization

Notes to Consolidated Financial Statements December 31, 2021 and 2020

are removed from the accounts and any resulting gains or losses are included in changes in net assets.

Construction in progress is recorded at cost. The Organization capitalizes construction, insurance and other costs during the period of construction. Depreciation and amortization are recorded when construction is substantially complete and the assets are placed in service.

According to federal regulations, any property and equipment obtained through federal funds are subject to a lien by the federal government. Provided that the Center maintains its tax-exempt status and the property and equipment are used for their intended purpose, the Center is not required to reimburse the federal government. If the stated requirements are not met, the Center would be obligated to the federal government in an amount equal to the fair value of the property and equipment.

Impairment of long-lived assets

The Organization reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In performing a review for impairment, the Organization compares the carrying value of the assets with their estimated future undiscounted cash flows. If it is determined that impairment has occurred, the loss would be recognized during that period. The impairment loss is calculated as the difference between the asset's carrying value and the present value of estimated net cash flows or comparable market values, giving consideration to recent operating performance and pricing trends. The Organization does not believe that any material impairment currently exists related to its long-lived assets.

Deferred rent

The Organization occupies space under leases containing escalation clauses and/or incentives that require normalization of the rental expense over the life of the leases. The resulting deferred rent is reflected in the accompanying consolidated statements of financial position.

Contributions

Transactions where the resource provider often receives value indirectly by providing a societal benefit, although the societal benefit is not considered to be of commensurate value, are deemed to be contributions. Contributions are classified as either conditional or unconditional. A conditional contribution is a transaction where the Organization has to overcome a barrier or hurdle to be entitled to the resource and the resource provider is released from the obligation to fund or has the right of return of any advanced funding if the Organization fails to overcome the barrier. The Organization recognizes the contribution revenue upon overcoming the barrier or hurdle. Any funding received prior to overcoming the barrier is recognized as refundable advance.

Unconditional contributions are recognized as revenue and receivable when the commitment to contribute is received.

Conditional and unconditional contributions are recorded as either with donor restriction or without donor restriction. Contributions are recognized as contributions with donor restrictions if they are received with donor stipulations that limit the use of the donated asset. Contributions received with no donor stipulations are recorded as contributions without donor restrictions. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified as net assets without donor restrictions and are reported in the statements of activities and changes in net assets as net assets

Notes to Consolidated Financial Statements December 31, 2021 and 2020

released from restriction. Donor-restricted contributions whose restrictions expire during the same fiscal year are recognized as contribution without donor restrictions.

At December 31, 2021, the Organization has received grants and contracts from governmental entities, accounted for as exchange transactions, in the aggregate amount of approximately \$7,000,000 that have not been recorded in the accompanying consolidated financial statements. These grants and contracts require the Organization to complete certain performance obligations during specified periods. If such performance obligations are not provided during the specified periods, the governmental entities are not obligated to expend the funds allotted under the contracts.

Grants and contracts revenue

Revenue from grants and contracts with resource providers such as the government and its agencies, other organizations and private foundations are accounted for either as exchange transactions or as contributions. When the resource provider receives commensurate value in return for the resources transferred to the Organization, the revenue from the grant or contract is accounted for as an exchange transaction. For purposes of determining whether a transfer of asset is a contribution or an exchange, the Organization deems that the resource provider is not synonymous with the general public, i.e., indirect benefit received by the public as a result of the assets transferred is not deemed equivalent to commensurate value received by the resource provider. The execution of a resource provider's mission or the positive sentiment from acting as a donor is not deemed to constitute commensurate value received by a resource provider.

Revenue from grants and contracts that are accounted for as exchange transactions is recognized when performance obligations have been satisfied. Absent donor stipulations to the contrary, grants and contracts awarded for the acquisition of long-lived assets are reported as nonoperating revenue during the fiscal year in which the assets are acquired. Cash received in excess of revenue recognized is recorded as refundable advances. Grants and contract transactions where the resource provider does not receive commensurate value are accounted for as a contribution.

Patient services revenue

Patient care service revenue is reported at the amount that reflects the consideration to which the Center expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Center bills the patients and third-party payors several days after the services are performed or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Center. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Center believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligations based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients receiving services in the Center's outpatient centers. The Center measures the performance obligation from the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of completion of the outpatient services. Revenue for performance obligations satisfied at a point in time is generally recognized when services are provided to patients and the Center does

Notes to Consolidated Financial Statements December 31, 2021 and 2020

not believe it is required to provide additional goods or services related to the provision of healthcare services.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Center has elected to apply the optional exemption provided and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The Center's performance obligations consist primarily of outpatient services that occur within one day of a patient's visit, thus, there were no unsatisfied or partially unsatisfied performance obligations at the end of the reporting period.

The Center determines the transaction price based on standard charges for services provided, reduced by contractual adjustments provided to third party payors, discounts provided to uninsured patients in accordance with the Center's policy, and implicit price concessions provided to uninsured patients. The Center determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Center determines its estimate of implicit price concessions based on its historical collection experience with this class of patients.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

Medicare - Outpatient services are paid using prospectively determined rates.

Medicaid - Reimbursements for Medicaid services are generally paid at prospectively determined rates per visit or per covered member.

Other - Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per visit, discounts from established charges, and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. Because of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Center's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Center. In addition, the contracts the Center has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the Center's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information

Notes to Consolidated Financial Statements December 31, 2021 and 2020

becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price were not significant in 2021 and 2020.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Center also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or by law, from standard charges. The Center estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. For the years ended December 31, 2021 and 2020, no additional revenue was recognized due to changes in its estimates of implicit price concessions, discounts, and contractual adjustments for performance obligations satisfied in prior years.

Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense.

Consistent with the Center's mission, care is provided to patients regardless of their ability to pay. Therefore, the Center has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (for example, copays and deductibles). The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts the Center expects to collect based on its collection history with those patients.

The Center is open to all patients, regardless of their ability to pay. In the ordinary course of business, the Center renders services to patients who are financially unable to pay for healthcare. The Center provides care to these patients who meet certain criteria under its sliding fee discount policy without charge or at amounts less than the established rates. Charity care services are computed using a sliding fee scale based on patient income and family size. The Center maintains records to identify and monitor the level of sliding fee discount it provides. For uninsured self-pay patients that do not qualify for charity care, the Center recognizes revenue on the basis of its standard rates for services provided or on the basis of discounted rates, if negotiated or provided by policy. On the basis of historical experience, a significant portion of the Center's uninsured patients will be unable or unwilling to pay for the services provided. Thus, the Center records an explicit concession to uninsured patients in the period the services are provided based on historical experience.

Community benefit represents the cost of services for Medicaid, Medicare and other public patients for which the Center is not reimbursed.

Based on the cost of patient services, charity care and community benefit for the years ended December 31 amounted to the following:

	 2021	 2020
Charity care Community benefit	\$ 70,000 6,000,000	\$ - 5,600,000

Notes to Consolidated Financial Statements December 31, 2021 and 2020

Such amounts determined to qualify as charity care are not reported as revenue. The Center has not changed its charity care or uninsured discount policies during fiscal years 2021 and 2020.

The Center has elected the practical expedient and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Center's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Center does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

The Center has applied the practical expedient and all incremental customer contract acquisition costs are expensed as they are incurred, as the amortization period of the asset that the Center otherwise would have recognized is one year or less in duration.

340B pharmacy program receivable and revenue

The Center participates in Section 340B of the Public Health Service Act ("PHS Act"), *Limitation on Prices of Drugs Purchased by Covered Entities* through its agreement with certain unaffiliated pharmacies. Participation in this program allows the Center to purchase pharmaceuticals at discounted rates for prescriptions to eligible patients. Revenue for performance obligations satisfied at a point in time is generally recognized when goods are provided to the Center's pharmacy patients and the Center does not believe it is required to provide additional goods or services related to that sale. The Center recognized pharmacy revenue of \$7,391,465 and \$8,054,673 for the years ended December 31, 2021 and 2020, respectively, and pharmacy receivable of \$794,846 and \$463,515 as of December 31, 2021 and 2020, respectively. The pharmacy receivable at December 31, 2019 was \$591,844.

Because all of its performance obligations relate to pharmacy sales contracts with a duration of less than one year, the Center has elected to apply the optional exemption and did not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The Center's performance obligations in relation to pharmacy revenue consist primarily of pharmacy sales that occur as the patient purchases the prescription and there were no unsatisfied or partially unsatisfied performance obligations at the end of the reporting period.

The Center determines the transaction price based on standard charges for prescriptions provided, reduced by contractual adjustments provided to third party payors, discounts provided to uninsured patients in accordance with the Center's policy, and implicit price concessions provided to uninsured patients. The Center determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Center determines its estimate of implicit price concessions based on its historical collection experience with this class of patients.

Concentrations of credit risk

Financial instruments that potentially subject the Organization to concentrations of credit risk consist principally of cash, patient services receivable and grants and contracts receivable. The Organization places its cash with high-quality financial institutions. The Organization monitors its financial institutions and the concentration of credit risk on a regular basis and does not anticipate nonperformance by the financial institutions. Patient services receivable credit risk is limited because the receivables are reported at their outstanding unpaid balances reduced by an allowance for doubtful accounts when applicable. The Organization estimates doubtful accounts

Notes to Consolidated Financial Statements December 31, 2021 and 2020

based on historical bad debts, factors related to specific payors' ability to pay and current economic trends.

In-kind contributions

Donated vaccines are recognized in the accompanying consolidated financial statements based on fair value at the date of donation. In 2021 and 2020, donated vaccines received amounted to \$620,920 and \$392,302, respectively.

Interest earned on federal funds

Interest earned on federal funds is recorded as a payable to the United States Public Health Services ("PHS") in compliance with the regulations of the United States Office of Management and Budget.

Functional expenses

The costs of providing program and other activities have been summarized on a functional basis in the statement of functional expenses. Accordingly, certain costs have been allocated among program services, general and administrative and fundraising services benefited. Such allocations are determined by management on an equitable basis. The expenses that are allocated are salaries, wages and fringe benefits and travel, which are allocated on the basis of time and effort; occupancy and facility costs and depreciation and amortization, which are allocated on the basis of square footage; medical and dental supplies, which are allocated on the basis of percentage of gross patient revenue; and professional fees, consultants and contractual services, information, technology and data processing and telephone, cable and cell phones, which are allocated on the basis of full time equivalent.

Performance indicator

The consolidated statements of activities and changes in net assets include changes in net assets without donor restrictions as the performance indicator. Changes in net assets with donor restrictions are excluded from the performance indicator.

Deferred compensation

The Organization has a deferred compensation arrangement for certain employees. Funds are held in a group annuity contract issued by an insurance company. At December 31, 2021 and 2020, the fair value of the group annuity contract was \$447,503 and \$404,382, respectively.

The contract issuer is contractually obligated to repay the principal and interest at a specified interest rate that is guaranteed. The crediting rate is based on a formula established by the contract issuer but may not be less than 0%. The crediting rate is reviewed on a quarterly basis for resetting.

Tax status

The Center and the Foundation were incorporated as not-for-profit corporations under the laws of the State of New York and are exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code. Therefore, there is no provision for income taxes. The Organization has no unrecognized tax benefits at December 31, 2021 and 2020. The Organization's federal and state income tax returns prior to fiscal year 2018 are closed and management continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

The Organization recognizes interest and penalties associated with tax matters as operating expenses, and include accrued interest and penalties with accrued expenses in the consolidated statements of financial position.

Notes to Consolidated Financial Statements December 31, 2021 and 2020

Subsequent events

The Organization has evaluated subsequent events through May 11, 2022, which is the date the consolidated financial statements were available to be issued.

Note 3 - Patient accounts receivable, net

Patient accounts receivable, net, consist of the following at December 31:

	 2021	2020
Medicaid	\$ 50,201	\$ 25,433
Medicaid Managed Care	1,069,375	672,942
Medicare	161,145	183,459
Self-pay	7,180	9,558
Private insurance	220,073	164,265
New York Safety Net Pool / Uncompensated Care	 296,162	 281,951
Total	\$ 1,804,136	\$ 1,337,608

There were no allowances for doubtful accounts at December 31, 2021 and 2020, respectively. The Center had \$0 and \$681,499 of write-offs for the years ended December 31, 2021 and 2020, respectively. Patient receivable bad debt for the years ended December 31, 2021 and 2020 was based on patient-specific impairment events. The Center has not changed its charity care or uninsured discount policies during fiscal years 2021 and 2020. The patient services receivable at December 31, 2019 was \$950,489.

Note 4 - Investments

At December 31, 2021 and 2020, investments consist of the following:

	20)21		20)20	
	 Cost		Fair value	 Cost		Fair value
Mutual funds Exchange traded funds Common stocks Corporate bonds U.S. government securities	\$ 5,047,616 7,793,555 253,650 1,792,992 8,629,308	\$	5,239,479 8,738,483 253,860 3,368,789 8,662,057	\$ 3,598,249 4,686,114 1,151,457 3,391,691 7,850,490	\$	4,035,564 5,380,370 1,274,443 3,554,865 8,050,937
Total	\$ 23,517,121	\$	26,262,668	\$ 20,678,001	\$	22,296,179

The Organization invests in various investment securities. Investment securities are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the statement of financial position.

Notes to Consolidated Financial Statements December 31, 2021 and 2020

Note 5 - Fair value measurements

The Organization values its financial assets based on the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

- Level 1 Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
- Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in inactive markets; or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated with observable market data.
- Level 3 Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, the Organization utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2021 and 2020.

Mutual funds and exchange-traded funds: Valued at the daily closing price as reported by the fund on the active market on which the individual mutual funds are traded.

Common stocks: Valued at the closing price reported on the active market on which the individual securities are traded.

Corporate bonds: Valued using pricing models maximizing the use of observable inputs for similar securities. This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings.

U.S. government securities: Valued using pricing models maximizing the use of observable inputs for similar securities.

Group annuity contract: Valued at fair value by the insurance company by discounting related cash flows based on current yields of similar instruments with comparable durations considering the credit-worthiness of the issuer.

Notes to Consolidated Financial Statements December 31, 2021 and 2020

The following tables set forth by level, within the fair value hierarchy, the Organization's investments as of December 31, 2021 and 2020:

	As	sets at fair value as	of December 31, 20)21
	Level 1	Level 2	Level 3	Total
-				
Mutual funds				
Stock funds	\$ 603,823	\$-	\$ -	\$ 603,823
Bond funds	3,059,157	-	-	3,059,157
Money market funds	1,576,499	-	-	1,576,499
Exchange traded funds				
Equity funds	6,350,485	-	-	6,350,485
Bond funds	2,387,998	-	-	2,387,998
Common stocks				
Energy	5,719	-	-	5,719
Financial	27,183	-	-	27,183
Healthcare	9,372	-	-	9,372
Utilities	15,308	-	-	15,308
Retail	19,007	-	-	19,007
Technology	97,731	-	-	97,731
Transportation	8,185	-	-	8,185
Consumer	71,355	-	-	71,355
Corporate bonds				
Investment grade	-	3,368,789	-	3,368,789
U.S. government securities	-	8,662,057	-	8,662,057
		· · · ·		, , ,
Total	\$ 14,231,822	\$ 12,030,846	\$-	\$ 26,262,668
		Assets at fair value a	s of December 31, 20	020
	Level 1	Level 2	Level 3	Total
Mutual funds				
Stock funds	\$ 541,797	\$-	\$-	\$ 541,797
Bond funds	3,086,943		Ψ -	3,086,943
Money market funds	406,825		-	406,825
Exchange traded funds	400,020			400,020
Equity funds	3,357,480	_	_	3,357,480
Bond funds	2,022,890		_	2,022,890
Common stocks	2,022,000	_	_	2,022,030
Energy	39,350	_	_	39,350
Financial	114,543		-	114,543
Healthcare		-	-	
	162,767	-	-	162,767
Industrial	92,212		-	92,212
Insurance	35,178		-	35,178
Pharmaceutical	64,599		-	64,599
Retail	335,597		-	335,597
Technology	358,117		-	358,117
Telecommunications	36,719		-	36,719
Utilities	35,360	-	-	35,360
Corporate bonds		• / • -		o == / oo=
Investment grade	-	3,554,865	-	3,554,865
U.S. government securities	-	8,050,937		8,050,937
	¢ 40.000.077	¢ 44.005.000	¢	¢ 00.000.470
Total	\$ 10,690,377	\$ 11,605,802	<u>\$ -</u>	\$ 22,296,179

Notes to Consolidated Financial Statements December 31, 2021 and 2020

There were no transfers among levels during the years ended December 31, 2021 and 2020. In such instances, the transfer is reported at the beginning of the reporting period.

The following tables set forth by level, within the fair value hierarchy, the Organization's deferred compensation as of December 31, 2021 and 2020:

		Deferred of	ompensa	ition at fair	value a	s of Decemb	er 31, 2	2021		
	Le	Level 1		Level 1 Level 2				Level 3	Total	
Group annuity contract	\$	_	\$	-	\$	447,503	\$	447,503		
		Deferred c	ompensa	ition at fair	value a	s of Decemb	er 31, 2	2020		
	Le	vel 1	Le	evel 2		Level 3	,	Total		
Group annuity contract	\$	-	\$	-	\$	404,382	\$	404,382		

The following table sets forth a summary of changes in the fair value of the Organization's level 3 assets for the years ended December 31, 2021 and 2020:

	2021			2020
Balance, beginning Unrealized (losses) gains	\$	404,382 43,121	\$	389,880 14,502
Balance, end	\$	447,503	\$	404,382

The following table represents the Organization's level 3 group annuity contract, the valuation techniques used to measure the fair values as of December 31, 2021 and 2020, respectively, and the significant unobservable inputs:

Investment	Fair	value 2021	Fair	value 2020	Principal valuation technique	Significant unobservable inputs	Range of significant input values	Weighted average
Group annuity contract	\$	447,503	\$	404,382	Discounted cash flow	Discount rate Duration (years)	3% - 4%	4%

Management determines the fair value measurement valuation policies and procedures, including those for Level 3 measurements. The Organization's Board of Directors assesses and approves these policies and procedures. Management uses the pricing data provided by the insurance carrier and evaluates a variety of factors including review of methods and assumptions used by the insurance carrier, recently executed transactions, existing contract, economic conditions, industry and market developments, and overall credit ratings.

Notes to Consolidated Financial Statements December 31, 2021 and 2020

Note 6 - Property and equipment, net

Property and equipment, net consists of the following:

	 2021	2020
Land Building Building and leasehold improvements Vehicles Equipment Furniture and fixtures Software	\$ 11,001 2,444,558 7,918,799 428,874 1,683,236 189,329 602,571	\$ 11,001 2,444,558 7,581,345 381,947 1,538,294 189,328 566,507
Subtotal Less accumulated depreciation and amortization Add construction in progress Total	\$ 13,278,368 (7,252,784) 81,755 6,107,339	\$ 12,712,980 (6,476,049) 7,466 6,244,397

In the event the DHHS grants are terminated, the DHHS reserves the right to transfer all property and equipment purchased with grant funds to the PHS or third parties.

Depreciation and amortization expense amounted to \$776,736 and \$797,264 in 2021 and 2020, respectively.

Note 7 - Line of credit

The Center has a revolving line of credit with a bank in the amount of \$750,000 that bears interest at a rate equal to the bank's prime rate plus 0.5%. The line of credit is secured by the Organization's personal property, fixtures and deposits. At December 31, 2021 and 2020, there was no outstanding balance.

Notes to Consolidated Financial Statements December 31, 2021 and 2020

Note 8 - Long-term debt

		20	021		2020
amount of ("PPP"). Economic to qualify average if are forgiv borrower eligible p forgivene employee unforgive interest r after the Business \$2,038,70	11, 2020, the Center received loan proceeds in the of \$2,038,700 under the Paycheck Protection Program Established as part of the Coronavirus Aid, Relief, and Security Act ("CARES Act"), the PPP provides for loans ing businesses in amounts up to 2.5 times the business's monthly payroll expenses. PPP loans and accrued interest rable after a "covered period" (24 weeks) as long as the maintains its payroll levels and uses the loan proceeds for urposes, including payroll, benefits, rent, and utilities. The ss amount will be reduced if the borrower terminates as or reduces salaries during the covered period. Any n portion of a PPP loan is payable over two years at an ate of 1.00%, with a deferral of payments for 10 months end of the covered period. On October 5, 2021, the Small Administration forgave the PPP loan and the amount of 00 is recorded as other revenue within the consolidated t of activities and changes in net assets.	\$	-	\$	2,038,700
Less curr	ent maturities		-	1	424,729
Long-terr	n portion	\$	-	\$	1,613,971

Note 9 - Net assets with donor restrictions

Net assets with donor restrictions at December 31, 2021 and 2020 consist of contributions received from the following organizations and individuals for specific programs and activities.

	2021								
	Balance January 1, 2021		2021 Additions		Released from Restrictions		_	Balance ember 31, 2021	
		2021	Additions		1.030100013			2021	
Whitney on Wheels Initiative	\$	144,050	\$	4,000	\$	-	\$	148,050	
Campaign for Smiles		26,746		-		-		26,746	
Childhood Literacy		129		100		-		229	
School Based Restorative / Access to Care		26,000		-		-		26,000	
Children's Dental Program		30,619		4,000		-		34,619	
Million Hearts Blood Pressure Monitoring		22,778		-		(3,528)		19,250	
Patient Portal		-		10,000		-		10,000	
Capacity Building Ambassador Program		2,265		-		-		2,265	
Collaborative Health Services		-		24,000		-		24,000	
Total	\$	252,587	\$	42,100	\$	(3,528)	\$	291,159	

Notes to Consolidated Financial Statements December 31, 2021 and 2020

	2020								
	Balance January 1, 2020		ļ	Released 2020 from Additions Restrictions		from		Balance cember 31, 2020	
Whitney on Wheels Initiative	\$	242,800	\$	108,250	\$	(207,000)	\$	144,050	
Campaign for Smiles		26,746		-		-		26,746	
Childhood Literacy		29		100		-		129	
School Based Restorative / Access to Care		26,000		-		-		26,000	
Children's Dental Program		2,849		29,500		(1,730)		30,619	
COVID-19		-		73,000		(73,000)		-	
Million Hearts Blood Pressure Monitoring		-		25,000		(2,222)		22,778	
Personal Protective Equipment		-		3,170		(3,170)		-	
Capacity Building Ambassador Program		2,265		-		-		2,265	
Total	\$	300,689	\$	239,020	\$	(287,122)	\$	252,587	

Note 10 - Patient services revenue (net of contractual allowances and discounts)

The composition of patient services revenue by major payor sources for the years ended December 31, 2021 and 2020 is as follows:

	 2021	2020
Medicaid	\$ 442,059	\$ 827,775
Medicaid Managed Care	6,418,135	5,996,429
Medicare	1,143,786	1,325,997
Self-pay	139,171	353,319
Private insurance	802,006	1,131,482
New York Safety Net Pool / Uncompensated Care	390,146	 425,616
Total	\$ 9,335,303	\$ 10,060,618

Revenue from patient's deductibles and coinsurance are included in the preceding categories based on the primary payor. Patient receivables consist of amounts due from government programs, commercial insurance companies, other group insurance programs, and private pay patients. Medicaid and Medicare revenue is reimbursed to the Center at the net reimbursement rates as determined by each program. Reimbursement rates are subject to revisions under the provisions of reimbursement regulations. Adjustments for such revisions are recognized in the fiscal year incurred.

Notes to Consolidated Financial Statements December 31, 2021 and 2020

Note 11 - DHHS grants

For the years ended December 31, 2021 and 2020, the Organization recognized grant revenue from the DHHS as follows:

Grant number	Grant Period	Total grant	Revenue recognized
6 H80CS00433-19-03 6 H80CS00433-20-07 1 H8DCS36560-01-01 4 H8ECS38870-01-01 1 H8FCS41484-01-00 5 H76HA00032-30-00 5 H76HA00032-31-01 1 H7CHA37134-01-00 5H79SM080547-03 5H79SM080547-04 Provider Relief Fund	04/01/20 - 03/31/21 04/01/21 - 03/31/22 04/01/20 - 03/31/21 05/01/20 - 04/30/22 04/01/21 - 03/31/23 05/01/20 - 04/30/21 05/01/21 - 04/30/22 04/01/20 - 03/31/21 09/30/20 - 09/29/21 09/30/21 - 09/29/22	 \$ 5,601,061 5,530,832 879,845 407,089 3,461,750 381,620 381,620 67,500 485,000 485,000 	<pre>\$ 1,962,329 3,532,629 879,845 302,311 17,100 108,152 262,955 31,415 328,849 18,266 202,333</pre>
Total DHHS revenue 2021			\$ 7,646,184
Grant number 6 H80CS00433-18-07 6 H80CS00433-19-03 1 H8CCS35180-01-00	Grant Period 04/01/19 - 03/31/20 04/01/20 - 03/31/21	Total grant \$ 5,968,311 5,601,061	Revenue recognized \$ 1,954,811
1 H8DCS36560-01-00 1 H8ECS38870-01-00 5 H76HA00032-29-00 5 H76HA00032-30-00 6H79SM080547-02M001 5H79SM080547-03 Provider Relief Fund	03/15/20 - 03/14/21 04/01/20 - 03/31/21 05/01/20 - 04/30/21 05/01/19 - 04/30/20 05/01/20 - 04/30/21 09/30/19 - 09/29/20 09/30/20 - 09/29/21	66,251 879,845 407,089 381,620 381,620 485,000	3,638,732 66,251 - - 178,263 273,468 365,034 156,151 -

Notes to Consolidated Financial Statements December 31, 2021 and 2020

Note 12 - Availability and liquidity

The following represents the Organization's financial assets at December 31, 2021 and 2020:

	 2021	 2020
Financial assets at year end		
Cash	\$ 5,722,143	\$ 5,842,536
Short-term investments	11,557,471	10,002,971
Patient accounts receivable, net	1,804,136	1,337,608
340B pharmacy program receivable	794,846	463,515
Grants and contracts and contributions receivable	 752,750	 760,053
Total financial assets	20,631,346	18,406,683
Less amounts not available to be used within one year Net assets with donor restrictions	291,159	252,587
Financial assets available to meet general expenditures over the next 12 months	\$ 20,340,187	\$ 18,154,096

The Center's goal is generally to maintain liquid financial assets to meet 90 days of operating expenses (approximately \$5.7 million). As part of its liquidity plan, excess cash is invested in short-term investments, including money market accounts and certificates of deposit. The Center has a \$750,000 bank revolving line of credit to meet cash flow needs. As of December 31, 2021 and 2020, there were no outstanding balances on this line of credit. The Center received a Small Business Administration Payment Protection Program loan in May 2020 for \$2,038,700 and this debt was categorized as a long-term liability on the balance sheet at December 31, 2020. On October 5, 2021, the Small Business Administration granted the Center's loan forgiveness filing, and this entire debt was extinguished, and then recorded as other revenue.

As of December 31, 2021, the Center has commitments to expand operations in the communities it serves with new and expanded health care facilities and offices, the costs of which will approximate \$4.6 million in property development, renovations and health care facility build-out costs to be paid from operations. A New York State Department of Health grant notice of award was received during 2019, but the grantee must pay for the construction costs before applying for grant drawdowns. Additional financial commitments in 2022 include investments into existing infrastructures and properties to improve patient care and patients' access to new services such as telemedicine technology. Further, a new electronic health record computer system was implemented in December 2020, which will require \$800,000 annually in software user fees. Additional electronic health record computer systems will be implemented in 2022, which include new behavioral health and dental software platforms.

The Center also maintains long-term investments held in securities traded on the open markets of \$14.9 million and \$12.4 million as of December 31, 2021 and 2020. These investment reserves are intended to fund future information technologies during years 2022 and beyond to include further buildout and expansion of an existing data warehouse population health management platform as well as a new dispensing and electronic health record system for the Center's substance use disorder programs (estimated at \$800,000). Further, additional cash reserves will be needed to meet the reserve requirements that New York State Department of Health (DOH) and Department

Notes to Consolidated Financial Statements December 31, 2021 and 2020

of Financial Services (DFS) and the managed care organizations ("MCOs") require for participation in downside risk bearing value based payment ("VBP") arrangements. The standard reserve amount is expected to be sixty days of premiums attached to the patients in the MCOs (estimated at \$3,100,000). The Center's membership in the Finger Lakes Independent Practice Association (FLIPA) will increase engagement in VBP contracts, which is likely to require these reserve requirements in any downside risk arrangements. The Center continues to evaluate potential merger activities with another local area health organization. If a merger were approved, investments into the early operational parity would be needed to enhance the combined entity. These investments involve both staff wage and benefit parity as well as infrastructure investments.

Note 13 - Pension plan

The Organization has a defined contribution pension plan covering substantiality all employees. The Organization makes a matching contribution equal to 200% of the employee's elective annual contributions up to a maximum limit of 2% of the employee's compensation after the employee reaches six months of service with no age requirement. Contributions total \$337,687 and \$388,100 for the years ended December 31, 2021 and 2020, respectively.

Note 14 - Related party transactions

In March 2015, the Center became one of five members of a limited liability company known as Alliance for Better Health Care, LLC ("the Alliance"). The Alliance was formed in response to a New York State Department of Health, DHHS-CMS supported initiative called the Delivery System Reform Incentive Payment Program ("DSRIP"). The shared goals of DSRIP and the Alliance are to achieve the so-called "Triple Aim" of improving patient care, improving the overall health and wellness of the communities served, and reducing health care costs. The Alliance has a DSRIP contract with the State of New York with the potential to earn up to \$237 million over the five-year DSRIP period, which was extended for another year through to March 31, 2021, and an additional \$13 million might be made available as part of certain high-performance pools. Based on the terms of the agreement between the Center and the Alliance, DSRIP funds are to be disbursed to the Alliance's members based on participation in each DSRIP project, as well as each member's individual performance in relation to the DSRIP metrics, to be determined by the Alliance, not based on each member's ownership in the Alliance. The Alliance operating agreement did not require the Center to contribute capital to the venture nor does it require any future investment in the operation of the Company. Based on the preceding circumstances, there is no determinable value assigned to the Center's investment in the Alliance, and no investment value is included in the Organization's consolidated financial statements.

During the years ended December 31, 2021 and 2020, the Organization recorded \$171,217 and \$1,383,350, respectively, in grant revenue related to its DSRIP contract with the Alliance, which is included in grant revenue in the Organization's consolidated statements of activities and changes in net assets. The Organization recorded \$1,152,021 and \$1,240,470 as refundable advances on the consolidated statements of financial position as of December 31, 2021 and 2020, respectively.

Notes to Consolidated Financial Statements December 31, 2021 and 2020

Note 15 - Commitments and contingencies

The Center has contracted with various funding agencies to perform certain healthcare services and receives Medicaid and Medicare revenue from the State and federal governments. Reimbursements received under these contracts and payments under Medicaid and Medicare are subject to audit by federal and state governments and other agencies. Upon audit, if discrepancies are discovered, the Center could be held responsible for reimbursing the agencies for the amounts in question.

The Center maintains its medical malpractice coverage under the Federal Tort Claims Act ("FTCA"). FTCA provides malpractice coverage to eligible PHS-supported programs and applies to the Center and its employees while providing services within the scope of employment included under grant-related activities. The Attorney General, through the U.S. Department of Justice, has the responsibility for the defense of the individual and/or grantee for malpractice cases approved for FTCA coverage.

The Center purchases professional and general liability insurance with a maximum limit of \$3,000,000, to cover medical malpractice claims not covered by the FTCA. There are no known claims or incidents that may result in the assertion of additional claims arising from services provided to patients as of December 31, 2021 and 2020.

On October 10, 2019, the Center reached a new collective bargaining agreement with its union, which covers approximately 18% of the Organization's employees. The agreement became effective July 1, 2019 and expires on June 30, 2022. The agreement provides for across the board salary increases of 3% effective July 1, 2019, and effective July 1, 2021, an across the board increase of 2.25%, and if health insurance premiums do not increase more than 10% over the 2021 premiums, an additional 0.5% will be added to the annual increase for a total possible increase of 2.75%.

The healthcare industry is subject to voluminous and complex laws and regulations of federal, state and local governments. Compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement laws and regulations, anti-kickback and anti-referral laws and false claims prohibitions. In recent years, government activity has increased with respect to investigations and allegations concerning possible violations of reimbursement, false claims, anti-kickback and anti-referral statutes and regulation by healthcare providers. The Center believes that it is in material compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. Upon audit, if discrepancies are discovered, the Center could be held responsible for refunding the amount in question.

The Organization entered into various lease agreements for the use of space that have been classified as operating leases and expire on various dates through to 2029. Rent expense paid for the years ended December 31, 2021 and 2020 was \$405,473 and \$312,200, respectively.

Notes to Consolidated Financial Statements December 31, 2021 and 2020

As of December 31, 2021, the Organization is obligated to make future minimum payments in each of the subsequent five years and thereafter as follows:

2022	\$ 299,871
2023	300,181
2024	264,331
2025	212,976
2026	82,692
Thereafter	 131,485
Total	\$ 1,291,536

In early 2020, an outbreak of a novel strain of coronavirus that causes COVID-19 emerged globally. As a result, events have occurred, including mandates from federal, state and local authorities that have caused business disruption leading to a significant decline in patient visits. While the disruption is currently expected to be temporary, there is considerable uncertainty around the duration of this impediment. Therefore, while the Organization expects this matter to negatively impact the Organization's financial condition, results of operations and cash flows, the extent of the financial impact and duration cannot be reasonably estimated at this time.

During March 2020, the Organization entered into a Letter of Intent with a local health care provider to perform due diligence efforts to explore a possible merger.

Supplementary Information

Schedule of Expenditures of Federal Awards Year Ended December 31, 2021

Federal Grantor/ Pass-through Grantor/Program or Cluster Title	Federal Assistance Listing Number	Pass-through Entity Identifying Number	Passed through to Subrecipients	Total Federal Expenditures
U.S. Department of Health and Human Services Direct Programs Health Center Program Cluster Health Center Program (Community Health Centers, Migrant Health Centers, Health Care for the Homeless,				
and Public Housing Primary Care)	93.224	N/A	\$ -	\$ 313,392
COVID-19 - Health Center Program (Community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public Housing Primary Care)	93.224	N/A	<u>-</u>	1,199,256
Subtotal Assistance Listing Number 93.224				1,512,648
Affordable Care Act (ACA) Grants for New and Expanded Services under the Health Center Program	93.527	N/A	<u> </u>	5,181,566
Total Health Center Program Cluster				6,694,214
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	N/A	-	371,107
COVID-19 - Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	N/A		31,415
Subtotal Assistance Listing Number 93.918				402,522
Substance Abuse and Mental Health Services - Projects of Regional and National Significance	93.243	N/A	-	347,115
COVID-19 - HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund	93.461	N/A	-	34,916
COVID-19 - Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution	93.498	N/A	-	202,333
Passed through New York State Department of Health Maternal and Child Health Services Block Grant to the States	93.994	DOH01- C32426GG- 3450000	-	29,267
Refugee and Entrant Assistance - State Administered Programs	93.566	DOH01- C35390GG- 3450000	-	10,474
Passed through HealthEfficient Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's	93.421	Not Available	-	2,500
Passed through Research Foundation for Mental Hygiene, Inc. Opioid STR	93.788	H79 TI083327-01		16,273_
Total U.S. Department of Health and Human Services				7,739,614
U.S. Department of Agriculture Passed through New York State Department of Health WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10.557	DOH01- C35435GG- 3450000	<u>-</u>	1,593,978
Total U.S. Department of Agriculture				1,593,978
Total Expenditures of Federal Awards			\$ -	\$ 9,333,592

See Notes to Schedule of Expenditures of Federal Awards.

Notes to Schedule of Expenditures of Federal Awards December 31, 2021

Note 1 - Basis of presentation

The accompanying schedule of expenditures of federal awards (the "Schedule") includes the federal award activity of Whitney M. Young, Jr. Health Center, Inc. (the "Center") under programs of the federal government for the year ended December 31, 2021. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the "Uniform Guidance"). Because the Schedule presents only a selected portion of the operations of the Center, it is not intended to and does not present the financial position, changes in net assets or cash flows of the Center.

Note 2 - Summary of significant accounting policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement.

Note 3 - Indirect cost rate

The Center has elected not to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

Note 4 - Nonmonetary assistance

Nonmonetary assistance is reported in the Schedule at the fair value of the Special Supplemental Nutrition Program for Women, Infants, and Children ("WIC") checks and Electronic Benefits Transfer ("EBT") or WIC cards received. The total federal share of the food instruments distributed by the Center amounted to \$1,148,580 and is included in the Schedule.

Note 5 - COVID-19 - Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution -Assistance Listing Number 93.498

For the DHHS awards related to the Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (PRF) program, DHHS has indicated the amounts on the schedule be reported corresponding to reporting requirements of the HRSA PRF Reporting Portal. Payments from DHHS for PRF are assigned to 'Payment Received Periods' (each, a Period) based upon the date each payment from the PRF was received. Each Period has a specified Period of Availability and timing of reporting requirements. Entities report into the HRSA PRF Reporting Portal after each Period's deadline to use the funds (i.e., after the end of the Period of Availability).

The Schedule includes \$202,333 received from DHHS between April 10, 2020 and April 24, 2020. In accordance with guidance from DHHS, this amount is presented as Period 1. The amount is recognized as DHHS grant revenue in the consolidated financial statements in the year ended December 31, 2021.

Note 6 - COVID-19 - HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund - Assistance Listing Number 93.461

For the DHHS award related to the HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund program (the Uninsured/CAF Program), the amount on the Schedule relates to the amount of revenue recognized in the consolidated financial statements during the year ended December 31, 2021.

CohnReznick LLP cohnreznick.com



Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Board of Directors Whitney M. Young, Jr. Health Center, Inc.

We have audited in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Whitney M. Young, Jr. Health Center, Inc. (the "Center"), which comprise the consolidated statements of financial position as of December 31, 2021 and 2020, and the related statements of activities and changes in net assets, functional expenses, and cash flows for the years then ended, and the related notes to the consolidated financial statements and have issued our report thereon dated May 11, 2022. The financial statements of Whitney M. Young, Jr. Foundation were not audited in accordance with *Government Auditing Standards* and, accordingly, this report does not include reporting on internal control over financial reporting or instances of reportable noncompliance associated with Whitney M. Young, Jr. Foundation.

Report on Internal Control over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Center's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Center's internal control. Accordingly, we do not express an opinion on the effectiveness of the Center's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit, we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Center's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

CohnReynickIIP

New York, New York May 11, 2022



Independent Auditor's Report on Compliance for Each Major Federal Program and Report on Internal Control over Compliance Required by the Uniform Guidance

To the Board of Directors Whitney M. Young, Jr. Health Center, Inc.

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Whitney M. Young, Jr. Health Center, Inc.'s (the "Center") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Center's major federal programs for the year ended December 31, 2021. The Center's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Center complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended December 31, 2021.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America ("GAAS"); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Center and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Center's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Center's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Center's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional



omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Center's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Center's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Center's internal control over compliance relevant to the audit in
 order to design audit procedures that are appropriate in the circumstances and to test and
 report on internal control over compliance in accordance with the Uniform Guidance, but not for
 the purpose of expressing an opinion on the effectiveness of the Center's internal control over
 compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiencies, in internal control over compliance with a type of compliance with a type of deficiencies, in internal control over compliance with a type of compliance that is less severe than a material weakness in internal control over compliance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance that weaknesses or significant deficiencies in internal control over compliance that we consider to be material control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Cohn Reznick ZP

New York, New York May 11, 2022

Schedule of Findings and Questioned Costs December 31, 2021

Section I - Summary of Auditor's Results

Financial Statements:

Type of report the auditor issued on whether the co financial statements audited were prepared in acco with GAAP:		Unmodifie	<u>d</u>
 Internal control over financial reporting: Material weakness(es) identified? Significant deficiency(ies) identified? 		yes yes	<u>√</u> no <u>√</u> none reported
Noncompliance material to financial statements not	ted?	yes	<u>√</u> no
Federal Awards:			
Internal control over major federal programs:			
Material weakness(es) identified?Significant deficiency(ies) identified?		yes yes	<pre>✓ no</pre> ✓ none reported
Type of auditor's report issued on compliance for major federal programs:		Unmodifie	<u>d</u>
Any audit findings disclosed that are required to be in accordance with 2 CFR 200.516(a)?	reported	_ yes	_✓ no
Identification of major federal programs:			
Assistance Listing Numbers(s)	Name of Federal	Program	
93.224	 U.S. Department of Health and Human Services: Health Center Program Cluster: Consolidated Health Centers, (Community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public Housing Primary Care) COVID-19 - Consolidated Health Centers, (Community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public Housing Primary Care) Affordable Care Act (ACA) Grants for New and Expanded Services Under the Health Center Program 		
93.527			
Dollar threshold used to distinguish between type A and B programs:		<u>\$750,000</u>	
Auditee qualified as low-risk auditee?		_✓_ yes	no

Schedule of Findings and Questioned Costs December 31, 2021

Section II - Financial Statement Findings

No matters reported

Section III - Federal Award Findings and Questioned Costs

No matters reported



Independent Member of Nexia International cohnreznick.com